Efficacy and Safety Study of SUNPG1623

PHASE2CompletedINTERVENTIONAL

Enrollment

391

Participants

Timeline

Start Date

April 19, 2017

Primary Completion Date

March 1, 2019

Study Completion Date

September 24, 2019

Conditions

Active Psoriatic Arthritis

Interventions

DRUG

SUNPG1623 I

injection

DRUG

SUNPG1623 II

injection

DRUG

SUNPG1623 III

injection

DRUG

SUNPG1623 IV

injection

DRUG

PLACEBO

injection

Trial Locations (1)

SPARC Site 1, Middleburg Heights

All Listed Sponsors

lead

Sun Pharmaceutical Industries Limited

INDUSTRY

NCT02980692 - Efficacy and Safety Study of SUNPG1623 | Biotech Hunter | Biotech Hunter